|  |  |
| --- | --- |
| **Cumulative statistics** | **Statistics of individuals expts.** |
| **Strains** | **Bacteria** | **Supplementation** | **No. of expts.** | **Median lifespan (days)****(treatment vs control)** | **Change in lifespan (%)** | **S.E.M.****(treatment vs control)** | **Control****No. of animals****(dead vs censored)** | **Treatment****No. of animals****(dead vs censored)** | **Median lifespan (days)****(treatment vs control)** | **Change in lifespan (%)** | ***p*-value** | **Control****No. of animals****(dead vs censored)** | **Treatment****No. of animals****(dead vs censored)** |
| N2 | OP50UV-killed | Glycine500 µM(treatment throughout entirelife)  | 7 | 30/25 | +20.0 | 0.34/0.34 | 780(570/210) | 780(538/242) | 31/26 | +19.2 | <0.0001 | 120(81/39) | 120(73/47) |
| 31/25 | +24.0 | <0.0001 | 120(97/23) | 120(75/45) |
| 31/29 | +6.8 | <0.0001 | 120(97/23) | 120(101/19) |
| 31/28 | +10.7 | <0.0001 | 120(89/31) | 120(95/25) |
| 28/21 | +33.3 | <0.0001 | 100(64/36) | 100(56/44) |
| 23/21 | +9.5 | <0.0001 | 100(78/22) | 100(72/28) |
| 28/21 | +33.3 | <0.0001 | 100(64/36) | 100(66/34) |
| N2 | OP50UV-killed | Glycine500 µM(treatment from egg to larval stage 4) | 3 | 21/21 | 0 | 0.49/0.38 | 300(206/94) | 300(166/134) | 23/21 | +9.5 | 0.184 | 100(64/36) | 100(54/46) |
| 21/21 | 0 | 0.953 | 100(78/22) | 100(69/31) |
| 21/21 | 0 | 0.371 | 100(64/36) | 100(43/57) |
| N2 | OP50UV-killed | Glycine500 µM(treatment from day1 to day3 of adulthood) | 3 | 25/21 | +19.0 | 0.70/0.37 | 300(206/94) | 300(191/109) | 25/21 | +19.0 | 0.0008 | 100(64/36) | 100(64/36) |
| 23/21 | +9.5 | <0.0001 | 100(78/22) | 100(70/30) |
| 30/21 | +42.9 | <0.0001 | 100(64/36) | 100(57/43) |
| N2 | OP50UV-killed | Glycine500 µM(treatment throughout adulthood only) | 3 | 25/21 | +19.0 | 0.79/0.37 | 300(206/94) | 300(164/136) | 28/21 | +33.3 | <0.0001 | 100(64/36) | 100(52/48) |
| 23/21 | +9.5 | <0.0001 | 100(78/22) | 100(56/44) |
| 28/21 | +33.3 | 0.0007 | 100(64/36) | 100(56/44) |
| N2 | OP50UV-killed | Glycine5 µM | 2 | 28/26 | +7.7 | 0.72/0.42 | 240(178/62) | 240(158/82) | 28/26 | +7.7 | <0.0001 | 120(81/39) | 120(75/45) |
| 27/25 | +8.0 | 0.001 | 120(97/23) | 120(83/37) |
| N2 | OP50UV-killed | Glycine50 µM | 2 | 31/26 | +19.2 | 0.48/0.42 | 240(178/62) | 240(164/76) | 31/26 | +19.2 | <0.0001 | 120(81/39) | 120(76/44) |
| 29/25 | +16.0 | <0.0001 | 120(97/23) | 120(88/32) |
| N2 | OP50UV-killed | Glycine5 mM | 2 | 26/26 | 0 | 0.48/0.42 | 240(178/62) | 240(146/94) | 26/26 | 0 | 0.169 | 120(81/39) | 120(70/50) |
| 27/25 | +8.0 | 0.147 | 120(97/23) | 120(76/44) |
| N2 | OP50UV-killed | Glycine10 mM | 2 | 24/26 | -7.7 | 0.54/0.42 | 240(178/62) | 240(174/66) | 24/26 | -7.7 | 0.283 | 120(81/39) | 120(92/28) |
| 25/25 | 0 | 0.852 | 120(97/23) | 120(82/38) |
| *metr-1**(ok521)* | OP50UV-killed | Glycine500 µM | 2 | 21/21 | 0 | 0.23/0.21 | 300(179/121) | 300(149/151) | 21/21 | 0 | 0.899 | 120(75/45) | 120(59/61) |
| 21/21 | 0 | 0.665 | 180(104/76) | 180(90/90) |
| *sams-1**(ok3033)* | OP50UV-killed | Glycine500 µM | 2 | 23/23 | 0 | 0.35/0.33 | 252(166/86) | 235(155/80) | 23/23 | 0 | 0.111 | 132(87/45) | 120(83/37) |
| 23/23 | 0 | 0.213 | 120(79/41) | 115(72/43) |
| N2 | OP50UV-killed | Serine5 mM(treatment throughout entirelife) | 5 | 28/22 | +27.3 | 0.49/0.37 | 564(397/167) | 564(396/168) | 29/24 | +20.8 | <0.0001 | 120(73/47) | 120(78/42) |
| 31/24 | +29.2 | <0.0001 | 144(116/28) | 144(94/50) |
| 25/21 | +19.0 | <0.0001 | 100(64/36) | 100(66/34) |
| 25/21 | +19.0 | <0.0001 | 100(78/22) | 100(75/25) |
| 28/21 | +33.3 | <0.0001 | 100(64/36) | 100(67/33) |
| N2 | OP50UV-killed | Serine5 mM(treatment from egg to larval stage 4) | 3 | 21/21 | 0 | 0.59/0.37 | 300(206/94) | 300(165/135) | 23/21 | +9.5 | 0.3241 | 100(64/36) | 100(45/55) |
| 18/21 | -14.3 | 0.4698 | 100(78/22) | 100(68/32) |
| 19/21 | -9.5 | 0.6297 | 100(64/3) | 100(52/48) |
| N2 | OP50UV-killed | Serine5 mM(treatment from day1 to day3 of adulthood) | 3 | 25/21 | +19.0 | 0.85/0.37 | 300(206/94) | 300(189/111) | 28/21 | +33.3 | <0.0001 | 100(64/36) | 100(60/40) |
| 21/21 | 0 | <0.01 | 100(78/22) | 100(68/32) |
| 30/21 | +42.9 | <0.0001 | 100(64/36) | 100(61/39) |
| N2 | OP50UV-killed | Serine 5 mM(treatment throughout adulthood only) | 3 | 25/21 | +19.0 | 0.72/0.37 | 300(206/94) | 300(191/109) | 28/21 | +33.3 | <0.0001 | 100(64/36) | 100(61/39) |
| 23/21 | +9.5 | <0.0001 | 100(78/22) | 100(61/39) |
| 28/21 | +33.3 | <0.0001 | 100(64/36) | 100(69/31) |
| *metr-1**(ok521)* | OP50UV-killed | Serine5 mM | 2 | 19/17 | +11.8 | 0.55/0.45 | 264(167/97) | 264(186/78) | 21/21 | 0 | 0.103 | 120(68/52) | 120(71/49) |
| 19/17 | +11.8 | 0.202 | 144(99/45) | 144(115/29) |
| *sams-1**(ok3033)* | OP50UV-killed | Serine5 mM | 2 | 22/24 | -8.3 | 0.91/0.64 | 264(185/79) | 264(150/114) | 20/20 | 0 | 0.146 | 120(67/53) | 120(63/57) |
| 24/24 | 0 | 0.347 | 144(118/26) | 144(87/57) |
| N2 | HT115(*gcst-1*) | - | 3 | 19/19 | 0 | 0.72/0.63 | 432(358/74) | 432(364/68) | 18/18 | 0 | 0.368 | 144(122/22) | 144(113/31) |
| 19/19 | 0 | 0.459 | 144(113/31) | 144(129/15) |
| 20/18 | +11.1 | 0.553 | 144(123/21) | 144(122/22) |
| N2 | HT115(*mel-32*) | - | 3 | 20/18 | +11.1 | 0.34/0.24 | 408(315/93) | 408(340/68) | 21/19 | +10.5 | <0.0001 | 120(76/44) | 120(92/28) |
| 18/18 | 0 | <0.001 | 144(126/18) | 144(127/17) |
| 20/18 | +11.1 | <0.0001 | 144(113/31) | 144(121/23) |